Skip to main content
. Author manuscript; available in PMC: 2021 Aug 6.
Published in final edited form as: Mol Cancer Ther. 2019 May 29;18(8):1439–1450. doi: 10.1158/1535-7163.MCT-18-0833

Figure 6. Sirt5 inhibition impairs the Mus81-induced transcriptional activity in gastric cancer cells.

Figure 6.

(A) Western blot showed the expression of Mus81 and ZEB1 in SGC7901 and BGC823 cells treated with Sirt5 siRNAs. (B) Cell migration analysis using Transwell assays in Sirt5 knockdown SGC7901 and BGC823 cells. Data are reported as the mean ± SD of three independent experiments (t test). (C) Western blot showed Mus81 expression in Mus81-overexpressing SGC7901 cells transfected with Sirt5 siRNAs. (D) Cell migration analysis using Transwell assays in Mus81-overexpressing SGC7901 cells transfected with Sirt5 siRNAs. Data are reported as the mean ± SD of three independent experiments (t test). (E) ChIP assays of Mus81 enrichment on ZEB1 promoter regions in cells transfected with Sirt5 siRNAs. Data are reported as the mean ± SD of three independent experiments (t test). (F) Western blot showed the expression of Sirt5, Mus81 and ZEB1 in SGC7901 and BGC823 cells treated with BRD4 siRNAs. (G) Western blot showed the expression of Sirt5, Mus81 and ZEB1 in SGC7901 and BGC823 cells treated with AZD5153. *, P < 0.05; **, P < 0.01; ns., not significant.